New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
12:55 EDTRCPT, RCPT, NVS, NVS, BIIB, BIIBSummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen and Biotech Analyst Werther discuss novel drugs for Multiple Sclerosis, including drugs manufactured by RCPT, NVS and BIIB, on an Analyst/Industry conference call to be held on May 21 at 1:30 pm.
News For RCPT;NVS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 19, 2014
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
06:06 EDTRCPTReceptos 3.6M share Secondary priced at $100.00
The deal size was increased to $360M from $325M. Credit Suisse and Leerink acted as joint book running managers for the offering.
November 18, 2014
12:42 EDTRCPTReceptos volatility at low end of range
Receptos overall option implied volatility of 53 compares to its 8-week average of 61 according to Track Data, suggesting decreasing price movement.
November 17, 2014
16:52 EDTNVSNovartis' LCZ696 could change course of heart failure for patients, study shows
New data on Novartis' investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction shows it has the potential to change the course of the disease for patients. In August, Novartis presented topline results from the landmark PARADIGM-HF study showing LCZ696 was superior to ACE inhibitor enalapril on key endpoints, including significantly reducing the risk of CV death or heart failure hospitalization. The new analyses being presented for the first time at the American Heart Association Scientific Sessions 2014, with a paper being simultaneously published in Circulation, show that versus enalapril, LCZ696 significantly: reduced the risk of dying suddenly by 20% in HFrEF patients 45% of CV deaths and 36% of all cause deaths are sudden; reduced first and subsequent HFrEF hospitalizations by 21% and 23% respectively; reduced hospitalizations for a cardiovascular reason or for any reason both by 16%; reduced the need for more intense treatment at home by 16%; reduced emergency room visits because of rapid symptom worsening by 30%.
16:02 EDTRCPTReceptos files to sell common stock, no amount given
Receptos intends to use the net proceeds received from this offering to fund continued development of its product candidate RPC1063 in ongoing and planned clinical trials for Relapsing Multiple Sclerosis, Ulcerative Colitis and Crohn's Disease, continued development of its in-licensed product candidate RPC4046 in an ongoing clinical trial for Eosinophilic Esophagitis, ongoing preclinical and research programs, and working capital and other general corporate purposes. Credit Suisse Securities and Leerink Partners LLC are acting as joint lead book-running managers for the offering. Evercore Group L.L.C. and BMO Capital Markets Corp. are acting as book-running managers. Wedbush PacGrow Life Sciences and Nomura Securities International, Inc. are acting as co-managers.
11:06 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
10:41 EDTRCPTReceptos 'priced beyond perfection,' may offer shares, TheStreetSweeper says
Subscribe for More Information
10:27 EDTRCPTReceptos mentioned cautiously by TheStreetSweeper
November 16, 2014
15:07 EDTNVSNovartis says arthritis drug secukinumab met primary endpoint
Subscribe for More Information
November 14, 2014
14:53 EDTNVSCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
07:14 EDTNVSAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
13:32 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
November 12, 2014
11:17 EDTNVSLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:18 EDTNVSUBS to hold a conference
Subscribe for More Information
08:13 EDTBIIBBoston Biotech to hold a conference
Subscribe for More Information
07:58 EDTNVSGenVec expects 2014 cash burn between $6M-$7M from Novartis collaboration
Subscribe for More Information
07:53 EDTRCPTLeerink to hold a tour
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use